Population genetics of dengue virus and transmission of dengue fever;Genética de las poblaciones virales y transmisión del dengue

Salud Publica de Mexico

Volumn 51, Issue SUPPL.3, 2009, Pages

  Falcón Lezama, Jorge ^a   Sánchez Burgos, Gilma Guadalupe ^b   Ramos Castañeda, José ^c  

^a Servicios de Salud del Estado de Morelos   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Dengue; Mexico; Molecular epidemiology; Transmision

Indexed keywords

CLASSIFICATION; DENGUE; DENGUE VIRUS; DISEASE TRANSMISSION; GENETICS; HUMAN; MEXICO; POPULATION GENETICS; REVIEW; SEROTYPING; VIROLOGY;

DENGUE; DENGUE VIRUS; GENETICS, POPULATION; HUMANS; MEXICO; SEROTYPING;

EID: 77957003121     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.1590/S0036-36342009000900006     Document Type: Article

References (50)

1. Rigau-Perez JG. Dengue and dengue haemorrhagic fever. Lancet 1998;352(9132): 971-977.
2. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239(4839): 476-481.
3. Sangkawibha N. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984;120(5): 653-669.
4. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007;85(1): 43-45.
5. Chevillon C, Failloux AB. Questions on viral population biology to complete dengue puzzle. Trends Microbiol 2003;11(9): 415-421.
6. Holmes EC. The evolutionary biology of dengue virus. Novartis Found Symp 2006;277:177-187; discussion 187-192, 251-253.
7. Holmes EC. Viral evolution in the genomic age. PLoS Biol 2007;5(10):278.
8. Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23-61.
9. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3(1):13-22.
10. Alvarez DE. Structural and functional analysis of dengue virus RNA. Novartis Found Symp 2006;277:120-32; discussion 132-135, 251-253.
11. Twiddy SS, Holmes EC, Rambaut A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol 2003;20(1):122-129.
12. Halstead SB. Dengue virus-mosquito interactions. Annu Rev Entomol 2008;53:273-291.
13. Leitmeyer KC. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999;73(6):4738-4747.
14. Vasilakis N. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology 2007;358(2): 402-412.
15. Armstrong PM, Rico-Hesse R. Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 2001;1(2):159-168.
16. Cologna R, Armstrong PM, Rico-Hesse R. Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol 2005;79(2):853-859.
17. Vasilakis N. Evolutionary processes among sylvatic dengue type 2 viruses. J Virol 2007;81(17):9591-9595.
18. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003;59: 315-341.
19. Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008;371(9611):500-509.
20. Alvarez DE. Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 2005;339(2):200-212.
21. Holden KL, Harris E. Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology 2004;329(1):119-133.
22. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11(3):480-496.
23. Nisalak A. Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg 2003;68(2):191-202.
24. Watts DM. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999;354(9188):1431-1434.
25. Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003;77(7):3929-3938.
26. Harris E. Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 2000;63(1-2):5-11.
27. Endy TP. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004;189(6):990-1000.
28. Rosen L. The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever. Am J Trop Med Hyg 1977;26(3):337-343.
29. Endy TP. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002;156(1):40-51.
30. Rico-Hesse R. Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 1990;174(2): 479-493.
31. Mota J. Phylogenetic analysis of the envelope protein (domain III) of dengue 4 viruses. Salud Publica Mex 2002;44(3):228-236.
32. Zanotto PM. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci U S A 1996;93(2):548-553.
33. Adams B, Boots M. Modelling the relationship between antibody-dependent enhancement and immunological distance with application to dengue. J Theor Biol 2006; 242(2):337-346.
34. Diaz FJ. Dengue virus circulation and evolution in Mexico: a phylogenetic perspective. Arch Med Res 2006;37(6):760-773.
35. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proc Natl Acad Sci U S A 2006;103(31):11802-11807.
36. Adams B. Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A 2006;103(38):14234-14239.
37. Rohani P. Population dynamic interference among childhood diseases. Proc Biol Sci 1998;265(1410):2033-2041.
38. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004;113(7):946-951.
39. Heffernan JM, Smith RJ, Wahl L.M. Perspectives on the basic reproductive ratio. J R Soc Interface 2005;2(4):281-293.
40. Cummings DA. Travelling waves in the occurrence of dengue haemorrhagic fever in Thailand. Nature 2004;427(6972):344-347.
41. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006;20(6):407-415.
42. Nagao Y, Koelle K. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc Natl Acad Sci U S A 2008;105(6):2238-2243.
43. Viboud C. Synchrony, waves, and spatial hierarchies in the spread of influenza. Science 2006;312(5772): 447-451.
44. Torres-Munoz A. Yellow fever in Mexico. The eradication of Aedes aegypti. 1966. Salud Publica Mex 1995;37(Suppl):S103-10; discussion S98.
45. Kaplan JE. Epidemiologic investigations of dengue infection in Mexico, 1980. Am J Epidemiol 1983;117(3):335-343.
46. Dirección General de Epidemiología, Secretaría de Salud. Panorama Epidemiológico (México). México, DF: DGE/SS, 2008.
47. Sánchez-Burgos G, López-Alvarado MA, Castaneda-Desales D, Ruiz-Gómez J, Ramos-Castaneda J. Prevalencia de anticuerpos neutralizantes contra los cuatro serotipos del virus Dengue en estudiantes universitarios del estado de Tabasco, México. Salud Publica Mex 2008;50(5):362-366.
48. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998;76(Suppl 2):22-25.
49. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis 2007;45(Suppl 1):S56-S60.
50. Chen ST. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008;453(7195):672-676.